SCHEMBL9047407

SCHEMBL9047407

CCCCCCCCCCCC(=O)[C@@]1(n2ccc(N)nc2=O)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.42
PDE4D Q08499 1/20 0.42
SLC29A1 Q99808 1/20 0.42
LMNA P02545 4/20 0.42
THRB P10828 1/20 0.42
MTOR P42345 1/20 0.42
MDM2 Q00987 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.35
FGFR1 P11362 2/20 0.34
PRKCA P17252 1/20 0.33
POLA1 P09884 1/20 0.33
CACNA1F O60840 2/20 0.32
ALB P02768 2/20 0.32
MAPT P10636 2/20 0.32
CACNA1D Q01668 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403455 1.00 PDE3A (0.42) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL31305353 1.00 PDE3A (0.42) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL31305348 0.95 PDE4D (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL6060509 0.92 PDE3A (0.45) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL4666818 0.85 PDE4D (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL2497496 0.85 PDE4D (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL29597277 0.84 PDE3A (0.44) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL8426900 0.83 PDE3A (0.41) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL236109 0.83 PDE3A (0.48) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL29860821 0.83 PDE3A (0.43) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP claimed
US-12186433-B2 Nanocapsules comprising modified nucleobases and/or nucleosides, hydrogels and oleogels comprising them and uses thereof Universite D'Angers France (FR) 2025-01-07 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12186433-B2 Nanocapsules comprising modified nucleobases and/or nucleosides, hydrogels and oleogels comprising them and uses thereof DUT, NT5C3B, NT5E PDE3A 630/4885PDE4D 260/4885SLC29A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.